Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2024-02-26 00:00:00 ET · period of report 2024-02-22 · accession 0001968202-24-000072 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-02-26 | 2024-02-22+ | REGN | SING GEORGE L | Dir | S - Sale+OE | $967.86 | -3,500 | 26.3K | -12% | -$3.39M |
| DM | 2024-02-26 | 2024-02-22+ | REGN | SING GEORGE L | Dir | M - OptEx | $413.33 | +3,500 | 26.8K | +15% | +$1.45M |
| DM | 2024-02-26 | 2024-02-22+ | REGN | SING GEORGE L | Dir | M - OptEx | $0.00 | -3,500 | 6,838 | -34% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-22 | S | D | 1,000 | $970.00 | 26,349 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-22 | M | A | 1,000 | $413.33 | 27,349 | D | — | — | |
| 3 | Common | Common Stock | 2024-02-23 | S | D | 500 | $985.00 | 26,349 | D | — | — | |
| 4 | Common | Common Stock | 2024-02-22 | M | A | 1,000 | $413.33 | 27,349 | D | — | — | |
| 5 | Common | Common Stock | 2024-02-22 | S | D | 1,000 | $960.00 | 26,349 | D | — | — | |
| 6 | Common | Common Stock | 2024-02-22 | S | D | 1,000 | $965.00 | 26,349 | D | — | — | |
| 7 | Common | Common Stock | 2024-02-22 | M | A | 1,000 | $413.33 | 27,349 | D | — | — | |
| 8 | Common | Common Stock | 2024-02-23 | M | A | 500 | $413.33 | 26,849 | D | — | — | |
| 9 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-02-23 | M | D | 500 | $0.00 | 6,338 | D | $413.33 · — to 2025-01-02 | 500 Common Stock | (F1) The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. |
| 10 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-02-22 | M | D | 3,000 | $0.00 | 6,838 | D | $413.33 · — to 2025-01-02 | 3,000 Common Stock | (F1) The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. |